RxDoctor Payments Data

Stephen Stack, MD

Family Medicine · Reynoldsburg, OHNPI 1316985146

Payments from drug & device makers

$12,247in general payments, 2019–2025

Across 810 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$857
  • GSK$828
  • Boehringer Ingelheim$677
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$12,192100%
  • Education$560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,247 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$100,423
Medicare patients
180
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$129,519
JardianceEmpagliflozin87$77,937
EliquisApixaban63$54,278
FarxigaDapagliflozin Propanediol54$49,169
Dupixent PenDupilumab13$48,589
MounjaroTirzepatide36$45,828
XareltoRivaroxaban33$34,388
JanuviaSitagliptin Phosphate37$33,272
TrulicityDulaglutide17$29,084
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,240
EntrestoSacubitril/Valsartan18$13,507
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,542
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$6,937
Levemir FlexpenInsulin Detemir11$5,271
Atorvastatin Calcium658$4,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,726$129,519102 claims
Boehringer IngelheimJardiance$677$77,93787 claims
Lilly USA, LLCMounjaro, Trulicity$857$74,91253 claims
PfizerEliquis$609$54,27863 claims
AstraZenecaFarxiga$1,373$49,16954 claims
Johnson & JohnsonXarelto$117$34,38833 claims
MerckJanuvia$313$33,27237 claims
GSKTrelegy Ellipta, Shingrix$828$26,78260 claims
NovartisEntresto$17$13,50718 claims
Sanofi-aventis U.S. LLCAdmelog$512$1,44315 claims
AbbVieSynthroid$1,446$1,25922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Reynoldsburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →